TCD STAT1−/− BM preserves GVT activity in relation to tumor growth but enhances overall survival after DLI and DC vaccination. (A) Lethally irradiated female recipients received TCD miHA-mismatched BM from female STAT1+/+ or STAT1−/− donors (129 → C3H.SW), and on day +14 received 20 × 106 DLI from female STAT1+/+ donors as well as 1 × 105 DCs from male STAT1+/+ donors. On day +28, a second dose of male DC vaccine was administered. Some recipients did not receive a DLI and a DC vaccine as a negative control for tumor protection. On day +42, 2 × 106 MB49 (which expresses the male antigen H-Y) was inoculated onto the right flank. (B) Tumors were measured in 2 dimensions twice weekly, and (C) alloHSCT recipients were followed for overall survival after tumor challenge. N = 5 mice/group, data are representative from 1 of 2 similar experiments. *P < .05.
